MIRM Mirum Pharmaceuticals, Inc.: Nilai bisnis marang pendapatan

Simbol resmi perusahaan Mirum (MIRM)

Mirum Pharmaceuticals generates revenue based on the sale of its patented drug LIVMARLI for children. Business valuation via EV/Sales confirms current market dynamics, where this metric equals 9846.69. Expanding its presence in Asia and Europe through distributors, combined with aggressive portfolio scaling and the pursuit of new medical indications, should ensure long-term capitalization growth for the company.

MIRM Rasio nilai perusahaan marang pendapatan Mirum Pharmaceuticals (23.11.2025 - 20.11.2026)

MIRM (Mirum): rincian analitis lan laporan miturut indikator

- rega pasar lan target rega analis:
Pambiji fundamental perusahaan:Mirum Pharmaceuticals MIRM
Sampel barang mirumpharma.com

This indicator compares the total enterprise value to sales volume, excluding the impact of debt load to determine the actual market value of one dollar of revenue. For Mirum Pharmaceuticals (MIRM), which focuses on a narrow segment of orphan liver diseases, the EV/Sales ratio reflects the efficiency of monetizing its developments, allowing the chart's price action to assess capital stability and the operational model's margin of safety.